- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01540201
The Effect of Different I:E Ratio on Gas Exchange of Patients Undergoing One-lung Ventilation for Lung Surgery
December 24, 2013 updated by: Sangmin M. Lee, Samsung Medical Center
Pulmonary gas exchange disturbance is a common anesthetic problem during one-lung ventilation (OLV) for thoracic surgery.
The inverse-ratio ventilation (IRV), which prolongs the inspiratory time greater than expiratory time, can be applied for adult respiratory distress syndrome.
The effect of IRV is to improve gas-exchange status by increasing mean airway pressure and alveolar recruitment.
We tried to evaluate the effect of IRV during OLV with lung protective strategy.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Pulmonary gas exchange disturbance is a common anesthetic problem during one-lung ventilation (OLV) for thoracic surgery.
Continuous positive airway pressure or positive end-expiratory pressure are usually applied to improve this disorder including hypoxia, but these methods are not enough.
The inverse-ratio ventilation (IRV), which prolongs the inspiratory time greater than expiratory time, can be applied for adult respiratory distress syndrome.
The effect of IRV is to improve gas-exchange status by increasing mean airway pressure and alveolar recruitment.
The application of IRV during OLV has not been performed to our knowledge, and there is a possibility of IRV to improve oxygenation during OLV.
There is a possibility of increase of auto-PEEP, or air trapping in subjects with chronic obstructive pulmonary disease, but this kind of auto-PEEP can be overcome by external PEEP.
Therefore, we tried to evaluate the effect of IRV during OLV with lung protective strategy.
Study Type
Interventional
Enrollment (Actual)
110
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 135-710
- Samsung Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- patients undergoing elective lung lobectomy surgery.
- the duration of one-lung ventilation is more than one hour.
- subjects with more than twenty years old.
Exclusion Criteria:
- subjects with past history of pneumothorax, asthma
- Age under 20, more than 70 years.
- Patients with ischemic heart disease, valvular heart disease
- patients with hemodynamic unstability
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: 1:2 group
conventional I:E ratio group, inspiratory time : expiratory time = 1:1
|
conventional I:E ratio of 1:2 is applied.
Ventilator : Datex-Ohmeda Aestiva/5 ® model
Other Names:
|
|
Experimental: 1:1 group
inspiratory time : expiratory time = 1:1
|
I:E ratio of 1:1 is applied Ventilator : Datex-Ohmeda Aestiva/5 ® model
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
arterial CO2 partial pressure
Time Frame: 10 minutes after induction of general anesthesia
|
arteial CO2 partial pressure
|
10 minutes after induction of general anesthesia
|
|
arterial CO2 partial pressure
Time Frame: 30 minutes after start of one-lung ventilation
|
arteial CO2 partial pressure
|
30 minutes after start of one-lung ventilation
|
|
arterial CO2 partial pressure
Time Frame: 60 minutes after start of one-lung ventilation
|
arteial CO2 partial pressure
|
60 minutes after start of one-lung ventilation
|
|
arterial CO2 partial pressure
Time Frame: 15 min after restart of TLV
|
arteial CO2 partial pressure
|
15 min after restart of TLV
|
|
arterial CO2 partial pressure
Time Frame: 1 hour after the end of surgery
|
arteial CO2 partial pressure
|
1 hour after the end of surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
respiratory compliance
Time Frame: 10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation
|
Dynamic compliance, Static compliance
|
10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation
|
|
arterial O2 partial pressure
Time Frame: 10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation, 1 hour after the end of surgery
|
arterial O2 partial pressure
|
10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation, 1 hour after the end of surgery
|
|
Mean airway pressure
Time Frame: 10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation
|
Mean airway pressure
|
10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation
|
|
tidal volume (exhaled)
Time Frame: 10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation
|
tidal volume (exhaled)
|
10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation
|
|
hemodynamic parameters
Time Frame: 10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation
|
systolic/ diastolic blood pressure, heart rate, mean blood pressure
|
10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation
|
|
end-tidal CO2 partial pressure
Time Frame: 10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation
|
end-tidal CO2 partial pressure
|
10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation
|
|
Dead space
Time Frame: 10 min after induction, 30 and 60 min after start of one lung ventilation, 15 min after restart of two-lung ventilation
|
physiologic dead space / tidal volume (VD/VT)
|
10 min after induction, 30 and 60 min after start of one lung ventilation, 15 min after restart of two-lung ventilation
|
|
work of breathing
Time Frame: 10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation
|
work of breathing
|
10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation
|
|
peak inspiratory pressure
Time Frame: 10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation
|
peak inspiratory pressure
|
10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation
|
|
plateau pressure
Time Frame: 10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation
|
plateau pressure
|
10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation
|
|
positive end-expiratory pressure
Time Frame: 10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation
|
positive end-expiratory pressure
|
10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation
|
|
minute ventilation
Time Frame: 10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation
|
minute ventilation
|
10 min after induction, 30 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Won Ho Kim, MD, Samsung Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2012
Primary Completion (Actual)
October 1, 2012
Study Completion (Actual)
October 1, 2012
Study Registration Dates
First Submitted
February 16, 2012
First Submitted That Met QC Criteria
February 27, 2012
First Posted (Estimate)
February 28, 2012
Study Record Updates
Last Update Posted (Estimate)
December 25, 2013
Last Update Submitted That Met QC Criteria
December 24, 2013
Last Verified
December 1, 2013
More Information
Terms related to this study
Other Study ID Numbers
- 2011-12-033-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
Beth Israel Deaconess Medical CenterDana-Farber Cancer Institute; MedWaves, IncRecruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)TerminatedStage IV Lung Cancer | Stage III Lung Cancer | Stage I Lung Cancer | Stage II Lung CancerUnited States
Clinical Trials on Conventional I:E ratio
-
Yonsei UniversityCompletedGeneral Anesthesia Using Endotracheal IntubationKorea, Republic of
-
Gangnam Severance HospitalCompletedBlood Loss, SurgicalKorea, Republic of
-
Samsung Medical CenterCompletedUterine Myoma | Ovarian Cyst | Laparoscopic Gynecologic SurgeryKorea, Republic of
-
Yonsei UniversityCompletedObese Patients, One Lung VentilationKorea, Republic of
-
Yonsei UniversityCompletedLung Cancer | Lung LobectomyKorea, Republic of
-
Başakşehir Çam & Sakura City HospitalCompletedAcute Respiratory Distress Syndrome (ARDS) | Ventilated Patient in Intensive CareTurkey
-
Gachon University Gil Medical CenterCompletedColorectal NeoplasmsKorea, Republic of
-
IRCCS Burlo GarofoloCompletedHematopoietic Stem Cell TransplantationItaly
-
Sohag UniversityNot yet recruiting
-
Ain Shams UniversityUnknown